Document is current
Any future updates will be listed below
-
Authors
Park, Se Whee Sammy https://orcid.org/0000-0002-1261-7505
Sundquist, Fredrik https://orcid.org/0000-0001-8290-0974
Teles, Leonor https://orcid.org/0009-0008-8941-4619
van Rooij, Rob https://orcid.org/0000-0001-8546-8283
Thor, Daniel https://orcid.org/0000-0003-4758-3170
Karlsson, Kasper https://orcid.org/0000-0003-0162-1354
Braat, Arthur J.A.T. https://orcid.org/0000-0002-8824-8697
Stenman, Jakob https://orcid.org/0000-0001-9543-3957
Nilsson, Joachim N. https://orcid.org/0000-0001-7496-9189
-
Funding
Funding for this research was provided by:
Karolinska Institute
- License Information
-
More Information
Article History
Received: 20 April 2026
Accepted: 1 June 2026
First Online: 19 June 2026
Declarations
Ethics approval: The study was conducted in accordance with ICH-GCP, EU-directive (2001/20/EC) and the Declaration of Helsinki. Ethical approval was obtained from the Swedish Ethical Review Authority (Dnr 2021 − 00470) and the Medical Research Ethics Committee of the Netherlands (CCMO NL78372.041.22).
Consent to participate: All patients and/or their legal guardians provided written informed consent prior to inclusion in the study.
Competing interests: Novartis supplied the study drugs Lutathera ® and LysaKare ® free of charge and provided partial financial support for the LuDO-N trial. AB is a consultant for Boston Scientific, Telix Pharmaceuticals and GE Healthcare, and receives research support from Boston Scientific, Telix Pharmaceuticals, GE Healthcare, Ariceum Therapeutics and Siemens Healthineers. JS and KK received research support from Novartis. JN, RR, LT, FS, SP, KK and DT have no competing interest to declare.
